Expression of Nociceptive Ligands in Canine Osteosarcoma

被引:13
|
作者
Shor, S. [1 ]
Fadl-Alla, B. A. [1 ]
Pondenis, H. C. [1 ]
Zhang, X. [2 ]
Wycislo, K. L. [2 ]
Lezmi, S. [2 ]
Fan, T. M. [1 ]
机构
[1] Univ Illinois, Dept Vet Clin Med, Urbana, IL 61802 USA
[2] Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA
关键词
Nociception; Osteoblast cytokines; Painful malignant osteolysis; TRANSITIONAL-CELL CARCINOMA; URINARY-BLADDER; CLINICAL-TRIAL; URETHRAL TUMORS; DOGS; PIROXICAM; CISPLATIN; MODEL; COMBINATION; MANAGEMENT;
D O I
10.1111/jvim.12511
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Canine osteosarcoma ( OS) is associated with localized pain as a result of tissue injury from tumor infiltration and peritumoral inflammation. Malignant bone pain is caused by stimulation of peripheral pain receptors, termed nociceptors, which reside in the localized tumor microenvironment, including the periosteal and intramedullary bone cavities. Several nociceptive ligands have been determined to participate directly or indirectly in generating bone pain associated with diverse skeletal abnormalities. Hypothesis: Canine OS cells actively produce nociceptive ligands with the capacity to directly or indirectly activate peripheral pain receptors residing in the bone tumor microenvironment. Animals: Ten dogs with appendicular OS. Methods: Expression of nerve growth factor, endothelin- 1, and microsomal prostaglandin E synthase- 1 was characterized in OS cell lines and naturally occurring OS samples. In 10 dogs with OS, circulating concentrations of nociceptive ligands were quantified and correlated with subjective pain scores and tumor volume in patients treated with standardized palliative therapies. Results: Canine OS cells express and secrete nerve growth factor, endothelin- 1, and prostaglandin E2. Naturally occurring OS samples uniformly express nociceptive ligands. In a subset of OS- bearing dogs, circulating nociceptive ligand concentrations were detectable but failed to correlate with pain status. Localized foci of nerve terminal proliferation were identified in a minority of primary bone tumor samples. Conclusions and Clinical Importance: Canine OS cells express nociceptive ligands, potentially permitting active participation of OS cells in the generation of malignant bone pain. Specific inhibitors of nociceptive ligand signaling pathways might improve pain control in dogs with OS.
引用
收藏
页码:268 / 275
页数:8
相关论文
共 50 条
  • [21] Feasibility and safety of whole lung irradiation in the treatment of canine appendicular osteosarcoma
    Brehm, Amanda
    Wilson-Robles, Heather
    Miller, Tasha
    Jarvis, Jill
    Deveau, Michael
    VETERINARY AND COMPARATIVE ONCOLOGY, 2022, 20 (01) : 20 - 28
  • [22] Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro
    McMahon, Melanie B.
    Bear, Misty D.
    Kulp, Samuel K.
    Pennell, Michael L.
    London, Cheryl A.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2010, 71 (07) : 799 - 808
  • [23] Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines
    Ong, S. M.
    Saeki, K.
    Tanaka, Y.
    Nishimura, R.
    Nakagawa, T.
    VETERINARY JOURNAL, 2016, 218 : 51 - 59
  • [24] Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times
    Selvarajah, Gayathri T.
    Kirpensteijn, Jolle
    van Wolferen, Monique E.
    Rao, Nagesha A. S.
    Fieten, Hille
    Mol, Jan A.
    MOLECULAR CANCER, 2009, 8 : 72
  • [25] Wnt/β-Catenin Expression Does Not Correlate with Serum Alkaline Phosphatase Concentration in Canine Osteosarcoma Patients
    Piskun, Caroline M.
    Muthuswamy, Anantharaman
    Huelsmeyer, Michael K.
    Thompson, Victoria
    Stein, Timothy J.
    PLOS ONE, 2011, 6 (10):
  • [26] Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
    Pinard, Christopher J.
    Hocker, Samuel E.
    Poon, Andrew C.
    Inkol, Jordon M.
    Matsuyama, Arata
    Wood, R. Darren
    Wood, Geoffrey A.
    Woods, J. Paul
    Mutsaers, Anthony J.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2022, 243
  • [27] Safety evaluation of the canine osteosarcoma vaccine, liveListeriavector
    Musser, Margaret L.
    Berger, Erika P.
    Tripp, Chelsea D.
    Clifford, Craig A.
    Bergman, Philip J.
    Johannes, Chad M.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2021, 19 (01) : 92 - 98
  • [28] The Association of Endothelin-1 Signaling with Bone Alkaline Phosphatase Expression and Protumorigenic Activities in Canine Osteosarcoma
    Neumann, Z. L.
    Pondenis, H. C.
    Masyr, A.
    Byrum, M. L.
    Wycislo, K. L.
    Fan, T. M.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2015, 29 (06) : 1584 - 1594
  • [29] Differences in Expression of Uroplakin III, Cytokeratin 7, and Cyclooxygenase-2 in Canine Proliferative Urothelial Lesions of the Urinary Bladder
    Sledge, D. G.
    Patrick, D. J.
    Fitzgerald, S. D.
    Xie, Y.
    Kiupel, M.
    VETERINARY PATHOLOGY, 2015, 52 (01) : 74 - 82
  • [30] Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells
    Fahey, Christine E.
    Milner, Rowan J.
    Kow, Kelvin
    Bacon, Nicholas J.
    Salute, Marc E.
    ANTI-CANCER DRUGS, 2013, 24 (05) : 519 - 526